IMMY17015 / Cellectar / Brea Lipe
Research Question:
Is the study drug, CLR 131, effective for the treatment of multiple myeloma or certain
lymphomas?
Basic Study Information
Purpose:
Part A of this study evaluates CLR 131 in patients with select B-cell malignancies
(multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic
lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell
lymphoma (DLBCL) who have been previously treated with standard therapy for their
underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating
IV administration of CLR 131 in patients with WM that failed Bruton's tyrosine kinase
inhibitors (BTKi).
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02952508?term=02952508&rank=1
Study Reference #: IMMY17015
Lead Researcher (Principal Investigator)
Lead Researcher:
Brea Lipe
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Lymphoma
More information about Multiple Myeloma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search